News Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Real-time Estimate Cboe BZX Other stock markets 14:51:01 29/04/2024 BST			5-day change	1st Jan Change
3.585 ^USD	+1.27%		+12.65%	-17.05%

04-09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
04-04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04-26	GL
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	04-10	AQ
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	04-09	GL
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	04-09	CI
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04-04	GL
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04-04	AQ
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04-04	CI
Tempest Therapeutics : Corporate Presentation - April 2024	03-29	PU
Tempest Therapeutics : Corporate Presentation - March 2024	03-22	PU
Tempest Reports Year End 2023 Financial Results and Provides Business Update	03-20	AQ
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Tempest Reports Year End 2023 Financial Results and Provides Business Update	03-19	GL
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K	03-19	PU
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	03-14	BU
Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	03-14	MT
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	03-12	GL
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	03-12	AQ
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	03-12	CI
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting	03-05	GL
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	02-26	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Summary

Filters